Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Intellipharmaceutics
Clients Purdue Pharma L.P.
Jones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of a Section 505(b)(2) New Drug Application to the FDA seeking approval of an extended-release oxycodone formulation.
Purdue Pharma L.P., et al. v. Intellipharmaceutics International Inc., et al., Nos. 1-17-cv-00392, 1-18-cv-00404 (D. Del.)